Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia

Abstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Met...

Full description

Bibliographic Details
Main Authors: Hayato Fujioka, Teruhiko Imamura, Tsutomu Koike, Shingo Yokoyama, Kota Kakeshita, Hidenori Yamazaki, Koichiro Kinugawa
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Renal Replacement Therapy
Subjects:
Online Access:https://doi.org/10.1186/s41100-023-00512-0
_version_ 1797556313099599872
author Hayato Fujioka
Teruhiko Imamura
Tsutomu Koike
Shingo Yokoyama
Kota Kakeshita
Hidenori Yamazaki
Koichiro Kinugawa
author_facet Hayato Fujioka
Teruhiko Imamura
Tsutomu Koike
Shingo Yokoyama
Kota Kakeshita
Hidenori Yamazaki
Koichiro Kinugawa
author_sort Hayato Fujioka
collection DOAJ
description Abstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Methods In this retrospective study, we embarked upon a comparative analysis encompassing the financial aspects, safety profiles, and efficacy metrics associated with SZC therapy and hemodialysis in patients grappling with acute hyperkalemia. No patients had systemic congestion or uremia. Results A total of 21 patients (median 81 years old, 14 men) were included; 14 received SZC therapy and seven underwent hemodialysis. Acute hyperkalemia improved immediately within several days without any procedure-related adverse events, regardless of therapeutic interventions (p < 0.05 for both). Total medical expenses were significantly lower in the SZC group than in the hemodialysis group (55,596 [43,652, 69,761] vs. 419,768 [354,270, 514,700] Japanese yen, p < 0.001). Conclusions In the realm of acute hyperkalemia management, SZC therapy emerges as an economically judicious alternative, while upholding parity in terms of safety and effectiveness when compared with the conventional hemodialysis paradigm—unless complicated by systemic congestion or uremia. The pressing task at hand revolves around the discernment of the optimal patient demographic for SZC therapy within the ambit of acute hyperkalemia.
first_indexed 2024-03-10T17:01:01Z
format Article
id doaj.art-990ed8c4a4c84241b01516be4eb6ba87
institution Directory Open Access Journal
issn 2059-1381
language English
last_indexed 2024-03-10T17:01:01Z
publishDate 2023-11-01
publisher BMC
record_format Article
series Renal Replacement Therapy
spelling doaj.art-990ed8c4a4c84241b01516be4eb6ba872023-11-20T10:59:04ZengBMCRenal Replacement Therapy2059-13812023-11-01911910.1186/s41100-023-00512-0Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemiaHayato Fujioka0Teruhiko Imamura1Tsutomu Koike2Shingo Yokoyama3Kota Kakeshita4Hidenori Yamazaki5Koichiro Kinugawa6The Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaAbstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Methods In this retrospective study, we embarked upon a comparative analysis encompassing the financial aspects, safety profiles, and efficacy metrics associated with SZC therapy and hemodialysis in patients grappling with acute hyperkalemia. No patients had systemic congestion or uremia. Results A total of 21 patients (median 81 years old, 14 men) were included; 14 received SZC therapy and seven underwent hemodialysis. Acute hyperkalemia improved immediately within several days without any procedure-related adverse events, regardless of therapeutic interventions (p < 0.05 for both). Total medical expenses were significantly lower in the SZC group than in the hemodialysis group (55,596 [43,652, 69,761] vs. 419,768 [354,270, 514,700] Japanese yen, p < 0.001). Conclusions In the realm of acute hyperkalemia management, SZC therapy emerges as an economically judicious alternative, while upholding parity in terms of safety and effectiveness when compared with the conventional hemodialysis paradigm—unless complicated by systemic congestion or uremia. The pressing task at hand revolves around the discernment of the optimal patient demographic for SZC therapy within the ambit of acute hyperkalemia.https://doi.org/10.1186/s41100-023-00512-0Chronic kidney diseasePotassium binderMedical cost
spellingShingle Hayato Fujioka
Teruhiko Imamura
Tsutomu Koike
Shingo Yokoyama
Kota Kakeshita
Hidenori Yamazaki
Koichiro Kinugawa
Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
Renal Replacement Therapy
Chronic kidney disease
Potassium binder
Medical cost
title Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
title_full Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
title_fullStr Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
title_full_unstemmed Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
title_short Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
title_sort sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
topic Chronic kidney disease
Potassium binder
Medical cost
url https://doi.org/10.1186/s41100-023-00512-0
work_keys_str_mv AT hayatofujioka sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia
AT teruhikoimamura sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia
AT tsutomukoike sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia
AT shingoyokoyama sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia
AT kotakakeshita sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia
AT hidenoriyamazaki sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia
AT koichirokinugawa sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia